181 related articles for article (PubMed ID: 38322113)
21. The Value of m5C-Related lncRNAs in the Prognostic Assessment and Immunotherapy of Stomach Adenocarcinoma.
He C; Zhu X; Kong F; Zhang X; Chai X; Zou C; Zhao D
Biomed Res Int; 2022; 2022():2747799. PubMed ID: 35711526
[TBL] [Abstract][Full Text] [Related]
22. Identification and characterization of a novel molecular classification incorporating oxidative stress and metabolism-related genes for stomach adenocarcinoma in the framework of predictive, preventive, and personalized medicine.
Dong Y; Yuan Q; Ren J; Li H; Guo H; Guan H; Jiang X; Qi B; Li R
Front Endocrinol (Lausanne); 2023; 14():1090906. PubMed ID: 36860371
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive analysis of peroxisome proliferator-activated receptors to predict the drug resistance, immune microenvironment, and prognosis in stomach adenocarcinomas.
Jia Q; Li B; Wang X; Ma Y; Li G
PeerJ; 2024; 12():e17082. PubMed ID: 38529307
[TBL] [Abstract][Full Text] [Related]
24. Constructing a novel gene signature derived from oxidative stress specific subtypes for predicting survival in stomach adenocarcinoma.
Zhou R; Peng N; Li W
Front Immunol; 2022; 13():964919. PubMed ID: 36059494
[TBL] [Abstract][Full Text] [Related]
25. A 13-Gene Metabolic Prognostic Signature Is Associated With Clinical and Immune Features in Stomach Adenocarcinoma.
Ye Z; Zheng M; Zeng Y; Wei S; Huang H; Wang Y; Liu Q; Lin Z; Chen S; Zheng Q; Chen L
Front Oncol; 2021; 11():612952. PubMed ID: 34235071
[TBL] [Abstract][Full Text] [Related]
26. A Prognostic Signature Constructed by
Han S; Zhu W; Yang W; Guan Q; Chen C; He Q; Zhong Z; Zhao R; Xiong H; Han H; Li Y; Sun Z; Hu X; Tian J
Front Genet; 2021; 12():646818. PubMed ID: 34512711
[TBL] [Abstract][Full Text] [Related]
27. Development of a prognostic metabolic signature in stomach adenocarcinoma.
Gong Y; Wu S; Dong S; Chen S; Cai G; Bao K; Yang H; Jiao Y
Clin Transl Oncol; 2022 Aug; 24(8):1615-1630. PubMed ID: 35355155
[TBL] [Abstract][Full Text] [Related]
28. ClC-3/SGK1 regulatory axis enhances the olaparib-induced antitumor effect in human stomach adenocarcinoma.
Gu Z; Wang L; Yao X; Long Q; Lee K; Li J; Yue D; Yang S; Liu Y; Li N; Li Y
Cell Death Dis; 2020 Oct; 11(10):898. PubMed ID: 33093458
[TBL] [Abstract][Full Text] [Related]
29. Construction of a prognostic risk model for Stomach adenocarcinoma based on endoplasmic reticulum stress genes.
Li X; Lei Y
Wien Klin Wochenschr; 2024 Jun; 136(11-12):319-330. PubMed ID: 37993598
[TBL] [Abstract][Full Text] [Related]
30. Identification of RFX5 as prognostic biomarker and associated with immune infiltration in stomach adenocarcinoma.
Guo L; Liu D
Eur J Med Res; 2022 Aug; 27(1):164. PubMed ID: 36045400
[TBL] [Abstract][Full Text] [Related]
31. METTL3 regulates N6-methyladenosine modification of ANGPTL3 mRNA and potentiates malignant progression of stomach adenocarcinoma.
Zhang Z; Fu J; Zhang Y; Qin X; Wang Y; Xing C
BMC Gastroenterol; 2023 Jun; 23(1):217. PubMed ID: 37344779
[TBL] [Abstract][Full Text] [Related]
32. Establishment of the molecular subtypes and a risk model for stomach adenocarcinoma based on genes related to reactive oxygen species.
Li G; Ping M; Zhang W; Wang Y; Zhang Z; Su Z
Heliyon; 2024 Mar; 10(5):e27079. PubMed ID: 38463816
[TBL] [Abstract][Full Text] [Related]
33. Identification of prognosis-related genes in the tumor microenvironment of stomach adenocarcinoma by TCGA and GEO datasets.
Ren N; Liang B; Li Y
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33015704
[TBL] [Abstract][Full Text] [Related]
34. Immunobiological signatures and the emerging role of SPP1 in predicting tumor heterogeneity, malignancy, and clinical outcomes in stomach adenocarcinoma.
Wu Y; Ren L; Tang Y; Zhu Z; Liu S; Jiang Y; Zhang S; Zhuang X; Chen Y
Aging (Albany NY); 2023 Oct; 15(20):11588-11610. PubMed ID: 37889539
[TBL] [Abstract][Full Text] [Related]
35. Glutamine metabolism genes prognostic signature for stomach adenocarcinoma and immune infiltration: potential biomarkers for predicting overall survival.
Li H; Wu Z; Zhang Y; Lu X; Miao L
Front Oncol; 2023; 13():1201297. PubMed ID: 37377916
[TBL] [Abstract][Full Text] [Related]
36. UBE2T promotes autophagy via the p53/AMPK/mTOR signaling pathway in lung adenocarcinoma.
Zhu J; Ao H; Liu M; Cao K; Ma J
J Transl Med; 2021 Aug; 19(1):374. PubMed ID: 34461934
[TBL] [Abstract][Full Text] [Related]
37. Identification of critical prognosis signature associated with lymph node metastasis of stomach adenocarcinomas.
Wang X; Zhang W; Guo Y; Zhang Y; Bai X; Xie Y
World J Surg Oncol; 2023 Feb; 21(1):61. PubMed ID: 36823639
[TBL] [Abstract][Full Text] [Related]
38. Construction and validation of a glycolysis-related lncRNA signature for prognosis prediction in Stomach Adenocarcinoma.
Liao T; Lu Y; Li W; Wang K; Zhang Y; Luo Z; Ju Y; Ouyang M
Front Genet; 2022; 13():794621. PubMed ID: 36313430
[No Abstract] [Full Text] [Related]
39. Multi-omics profiling and digital image analysis reveal the potential prognostic and immunotherapeutic properties of CD93 in stomach adenocarcinoma.
Wu B; Fu L; Guo X; Hu H; Li Y; Shi Y; Zhang Y; Han S; Lv C; Tian Y
Front Immunol; 2023; 14():984816. PubMed ID: 36761750
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of the immune and prognostic implication of MASP1 in stomach adenocarcinoma.
Zhang CH; Xu ZQ; Peng LL; Wang JJ; Gu HT
Eur Rev Med Pharmacol Sci; 2022 Sep; 26(18):6725-6741. PubMed ID: 36196721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
